Having trouble viewing this email? View in your browser.

Dear Colleagues

It is our pleasure to invite you to attend the Roche-sponsored symposium “Latest advances in diagnostic and treatment options for the COVID-19 pandemic: overcoming challenges in a rapidly evolving environment” at the virtual ECCMID 2021 congress.

During this one-hour session, we will examine the latest clinical data related to COVID-19 management across diagnosis and treatment options.

Professor Maria Vehreschild will contextualise patient decision-making using the latest diagnostic options to assist in the assessment and stratification of patients.

This will be followed by Professor François Raffi discussing the latest data on COVID-19 therapeutics across the clinical spectrum.

There will also be the opportunity to join our expert faculty in discussing the current and future outlook for managing COVID-19.

We hope you are able to join us for this engaging exploration of the impact that new diagnostic and treatment opportunities are having against this evolving global pandemic.

ESCMID-Appointed Chair:

Vitali Sintchenko
University of Sydney,

Symposium Chair:

Albert Osterhaus
TiHo Hannover,


13:15 – 13:20 Welcome and introductions

Vitali Sintchenko
University of Sydney, Australia

Professor Albert Osterhaus
TiHo Hannover, Germany

13:20 – 13:40 Case-based decision making: using SARS-CoV-2 diagnostic results

Maria Vehreschild
University Hospital Frankfurt, Germany

13:40 – 14:00 Treatment options for COVID-19: current landscape and future outlook

François Raffi
Nantes University Hospital, France

14:00 – 14:10 Discussion and Q&A

All faculty

14:10 – 14:15 Closing remarks

Albert Osterhaus
Vitali Sintchenko

This is a non-promotional educational meeting intended for HCPs outside the USA and may include scientific information about investigational compounds that are not approved or valid in your jurisdiction. M-XX-00005685


You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.